Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Not applicableActive Not RecruitingNCT01787409
What this trial is testing

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Who this might be right for
Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell Lymphoma+12 more
Mayo Clinic 565
Testing effectiveness (Phase 2)Active Not RecruitingNCT03598998
What this trial is testing

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Who this might be right for
Anaplastic Large Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Anaplastic Large Cell Lymphoma+17 more
City of Hope Medical Center 13
Early research (Phase 1)Ended earlyNCT00671112
What this trial is testing

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Who this might be right for
714leukemiaLymphoma
Brian Hill, MD, PhD 30
Testing effectiveness (Phase 2)WithdrawnNCT04795869
What this trial is testing

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Who this might be right for
Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell Lymphoma+11 more
Northwestern University
Testing effectiveness (Phase 2)Ended earlyNCT00810576
What this trial is testing

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 1